Efficacy of Second-Line Lenvatinib After Atezolizumab–Bevacizumab and Durvalumab–Tremelimumab in Unresectable Hepatocellular Carcinoma: Association with Prior Immunotherapy Response.
Saved in:
| Title: | Efficacy of Second-Line Lenvatinib After Atezolizumab–Bevacizumab and Durvalumab–Tremelimumab in Unresectable Hepatocellular Carcinoma: Association with Prior Immunotherapy Response. |
|---|---|
| Authors: | Kuzuya, Teiji1 (AUTHOR) teiji.kuzuya@fujita-hu.ac.jp, Muto, Hisanori1,2 (AUTHOR), Tachi, Yoshihiko1,3 (AUTHOR), Komura, Gakushi1 (AUTHOR), Nakano, Takuji1,2 (AUTHOR), Tanaka, Hiroyuki1,3 (AUTHOR), Nakaoka, Kazunori1 (AUTHOR), Funasaka, Kohei1 (AUTHOR), Nagasaka, Mitsuo1 (AUTHOR), Miyahara, Ryoji1 (AUTHOR), Ohno, Eizaburo1 (AUTHOR) |
| Source: | Cancers. Jul2026, Vol. 18 Issue 13, p2095. 17p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20726694 |
|---|---|
| DOI: | 10.3390/cancers18132095 |
